Search results
Found 16134 matches for
The US Food and Drug Administration (FDA) has recently licensed a form of ketamine – esketamine – as a treatment for depression which is resistant to other treatments. It is administered as a nasal spray in a clinic, initially twice a week, then weekly or fortnightly. Regular doses of the drug are necessary to prevent relapse.
SINAPPS2 Background & PPiP2 Recruitment Training Confirmation
The SINAPPS2 Trial is inviting people with acute psychosis symptom(s) and anti-neuronal membrane antibodies who have been identified through PPiP2 study to consent the trial and help testing the efficacy and safety of immunotherapy for antibody-associated psychosis.